Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 3/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21792176 | 0.93 | NOTUM (1.00) | NOTUMKCNH2ARRXRAGRIN1 | |
| SCHEMBL23451838 | 0.87 | NOTUM (1.00) | NOTUMKCNH2ARRXRAGRIN1 | |
| SCHEMBL19211518 | 0.78 | NOTUM (0.81) | NOTUMKCNH2RXRAGRIN1GRIN2B | |
| SCHEMBL23451926 | 0.77 | NOTUM (1.00) | NOTUM | |
| SCHEMBL17502291 | 0.74 | KCNH2 (1.00) | NOTUMKCNH2 | |
| SCHEMBL21792297 | 0.73 | NOTUM (0.74) | NOTUMKCNH2AR | |
| SCHEMBL28611957 | 0.73 | RXRA (0.69) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL19211413 | 0.73 | NOTUM (0.80) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL21792049 | 0.72 | NOTUM (1.00) | NOTUMKCNH2ARRXRAGRIN1 | |
| SCHEMBL12760739 | 0.72 | NOTUM (0.55) | NOTUMJAK2ROCK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885KCNH2 4732/4885AR 4711/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885KCNH2 4604/4885AR 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.